ClinicalTrials.govpublic full text
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
herpes zoster, shingles, shingles recurrence, hz, vaccine response rate, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 1032374
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.